

CURRICULUM VITAE

Note Biografiche

COGNOME E NOME: De Placido Sabino
NAZIONALITA': Italiana
DATA E LUOGO DI NASCITA: 15.5.1953 - Grottaminarda (AV)
STATO CIVILE: Coniugato, due figli

Posizione Accademica:

Settore Concorsuale

dal 28/10/2011 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA

Settore Scientifico Disciplinare

dal 14/03/2001 MED/06 - ONCOLOGIA MEDICA

Qualifica

Professore Ordinario

Anzianità nel ruolo di professore di I fascia

01/11/2000

Sede universitaria

Università degli Studi di NAPOLI "Federico II"

Dipartimento

Dipartimento di Medicina Clinica e Chirurgia

Via S. Pansini 5, 80131, Napoli ---Tel. 081-7462062 / 7463660 / 5457281 Fax 081-2203147

Curriculum degli studi

Ott. 1977	Laurea in Medicina e Chirurgia con voti 110 e lode/110, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II"
Nov. 1982	Specializzazione in "Medicina Interna" con voti 50 e lode/50, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II"
Lug. 1985	Specializzazione in "Oncologia" con voti 70 e lode/70, Facoltà di Medicina e Chirurgia, Università di Napoli "Federico II"

Ruoli Accademici

1991-2000	Professore Associato di Oncologia Medica della Facoltà di Medicina, Università "Federico II" Napoli
da Nov. 2000-	Professore Ordinario di Oncologia Medica della Facoltà di Medicina, Università "Federico II" Napoli

Esperienza Professionale e Requisiti di Capacità Gestionale ed Organizzativa:

In ambito Accademico

2006-2013	Direttore della Scuola di Specializzazione di Oncologia, Facoltà di Medicina, Università "Federico II" Napoli
2011-2012	Direttore del Dipartimento Scientifico di Endocrinologia ed Oncologia Molecolare e Clinica - Azienda Ospedaliera Universitaria, Università di Napoli Federico II
2013-2019	Coordinatore del corso di Laurea in Medicina e Chirurgia, Università di Napoli Federico II
2013-2020	Presidente della Commissione Nazionale con il compito di procedere alla revisione e all'incremento dell'archivio contenente i quesiti predisposti per la prova scritta degli Esami di Stato di abilitazione all'esercizio della professione di medico-chirurgo con nomina dal MIUR DM n. 256 del 04/05/2017
2017-oggi	Membro del Senato Accademico, Università di Napoli Federico II

In ambito Clinico-Assistenziale

1996-1997	Primario dell'Area Funzionale 'Terapie Oncologiche Speciali' del Dipartimento Assistenziale di Oncologia ed Endocrinologia Clinica, Azienda Universitaria Policlinico, Università di Napoli Federico II
-----------	---

1997-2013	Direttore di Unità Operativa Complessa 'Terapie Oncologiche Speciali' del Dipartimento Assistenziale di Endocrinologia ed Oncologia Molecolare e Clinica - Azienda Ospedaliera Universitaria, Università di Napoli Federico II
2016-oggi	Direttore del Centro Oncologico di Riferimento Polispecialistico Universitario o a carattere Scientifico (CORPUS) dell'AOU Federico II ai sensi di quanto previsto dal DCA n° 98 del 20.09.2016 sulla rete oncologica campana (ROC)
2018-oggi	Direttore Dipartimento Assistenziale Integrato (DAI) di "Onco-Ematologia, Diagnostica per Immagini e Morfologia e Medicina Legale" dell'AOU Federico II
2019-oggi	Direttore del Centro Regionale di Coordinamento Tumori Rari (CRCTR), AOU Federico II

In ambito Scientifico Nazionale

2012-oggi	Presidente, Consorzio "Oncotech" Il Consorzio coordina sperimentazioni cliniche cui partecipano circa 100 qualificate prestigiose Istituzioni oncologiche nazionali
2003-oggi	Vicepresidente del Comitato Etico di Ateneo, Università di Napoli Federico II;
2015-oggi 2009-2015	Past-President del Collegio degli Oncologi Medici Universitari (COMU) Presidente del Collegio degli Oncologi Medici Universitari (COMU)
2017-oggi	Membro del Comitato Tecnico Scientifico (CTS) dell'Istituto Nazionale Tumori di Napoli "Fondazione Pascale";
2008-2012	Membro del Comitato Tecnico Scientifico (CTS) dell'Istituto Nazionale Tumori di Napoli "Fondazione Pascale";
2007-2010	Membro della Commissione Nazionale Ricerca Sanitaria (CNRS) del Ministero della Salute, per nomina e decreto del Ministro della Salute (26-7-2007 / 26-7-2010);
2003	Nomina di "Esperto" della ESF (European Science Foundation) per il programma europeo di "European Survey on Bio-medical Research Infrastructures (Bio-med RI) nel campo della ricerca oncologica
2001-oggi	Coordinatore del Centro di Riferimento Regionale per la Prevenzione Oncologica (CRPO) per un programma di Prevenzione secondaria per il tumore della mammella e della cervice uterina
2000-oggi	Promotore e coordinatore di attività di ricerca del Gruppo Italiano Mammella (GIM) costituito da circa 100 centri nazionali. GIM promuove studi clinici innovativi sulla terapia del carcinoma mammario.

Incarichi Didattici

1988-oggi	Membro, ECTS Inner Circle (European Credit Transfer System)
-----------	---

2013-oggi	Delegato della Scuola di Medicina nella Commissione SOCRATES-ERASMUS di Ateneo dell'Università Federico II, per la pianificazione della mobilità di studenti e docenti nell'ambito dei Paesi Europei. In questa sua attività il Prof. De Placido ha contribuito a realizzare una rete con circa 32 università europee tra le maggiori, che permette a circa 60 studenti ogni anno di realizzare un periodo di studio all'estero
1988-2013	Coordinator, Life-long Learning-ERASMUS Commission Interuniversity Cooperation, School of Medicine and Surgery, University of Naples Federico II
1988-1992	Programma di Cooperazione Interuniversitario (PIC)(contratto n. ICP-I-1288/12) tra Paesi dell'Unione Europea per il Programma ERASMUS
1990-1993	Progetti Europei Comuni (PEC) (contratto n. JEP-4733-I) con Paesi di Est Europa per il Programma TEMPUS
2008-2013	Coordinatore del Corso integrato di "Oncologia Clinica" Facoltà di Medicina e Chirurgia, Università Federico II, Napoli
2008-2011	Membro del Collegio dei Docenti del Dottorato Internazionale " Oncologia ed Endocrinologia Molecolare"
2013-present	Membro del Collegio dei Docenti del Dottorato Internazionale "Terapie Avanzate Biomediche e Chirurgiche"

Fondi di Ricerca (selezionati)

PRIN 1998:	Biomolecular characterization of human neoplasias: diagnostic, prognostic and therapeutic implications. Durata: 24 mesi.
PRIN 2000:	Identification and validation of new markers of the metastasizing breast phenotype Durata: 24 mesi.
FAS grants CIPE 20/2004:	Analisi Tissutali. BIONCAM (Biobanca Oncologica Campania). Durata: 36 mesi.
AIRC 2005:	Breast Cancer: Preclinical and clinical development of therapeutic strategies. Durata: 36 mesi
POR Campania mis 3.16 2007:	Analisi Tissutali. BIONCAM (Biobanca Oncologica Campania). Durata: 36 mesi.
PRIN 2008:	Breast cancers and hormone sensitivity: new prognostic and predictive factors. Durata: 36 mesi
PON 01_01602 2009-2013:	Research and development of innovative biological drugs in oncology.
POR OcKey (Oncology and Cardiology Key Targets),	operative aim 2.1 of POR Campania 2007/2013 .
PON 03PE_00146_1:	Innovative biomarkers, biomaterials and drugs for the diagnosis and treatment of cerebral ischemia and of pluripharmaco-resistant tumors of the head, neck and breast through the creation of a network of biobanks.
PRIN 2015:	Useful experimental models for dissecting the molecular links between cancer development/progression and the obesity epidemic
Progetto SATIN:	Sviluppo di Approcci Terapeutici INnovativi per patologie neoplastiche resistenti ai trattamenti

Indicatori bibliografici:

- Numero di pubblicazioni in riviste scientifiche ad elevato controllo redazionale: **320**
- Numero di citazioni: **25302** (fonte Scopus)
- *H index*: **57** (fonte Scopus)

Elenco delle pubblicazioni

2020

1. Santoro C, Esposito R, Lembo M, Sorrentino R, De Santo I, Luciano F, Casciano O, Giuliano M, De Placido S, Trimarco B, Lancellotti P, Arpino G, Galderisi M.
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction.
Eur Heart J Cardiovasc Imaging. 2019 Dec 1;20(12):1345-1352.
doi: 10.1093/ehjci/jez194. PMID: 31326981
2. Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D.
Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.
J Natl Cancer Inst. 2020 May 14: djaa071.
doi: 10.1093/jnci/djaa071. Online ahead of print. PMID: 32407488
3. Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martínez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Cancer Treat Rev. 2020 Mar; 84:101965.
doi: 10.1016/j.ctrv.2020.101965. Epub 2020 Jan 17. PMID: 32000054
4. Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G.
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2020 Feb 10;12(2):408.
doi: 10.3390/cancers12020408. PMID: 32050629

5. Di Lorenzo G, Buonerba L, Ingenito C, Crocetto F, Buonerba C, Libroia A, Sciarra A, Ragone G, Sanseverino R, Iaccarino S, Napodano G, Imbimbo C, Leo E, Kozlakidis Z, De Placido S.
Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy.
Oncology. 2020 Jun 22;1-5. doi: 10.1159/000509434. Online ahead of print. PMID: 32570240

6. Carbognin L, Simbolo M, Calì A, Vicentini C, Delfino P, Sperduti I, Fassan M, Schettini F, Dieci MV, Griguolo G, Pilotto S, Fiorio E, Arpino G, Guarneri V, De Placido S, Conte P, Manfrin E, Brunelli M, Scambia G, Scarpa A, Tortora G, Bria E.
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model.
Breast. 2020 Apr; 50:56-63. doi: 10.1016/j.breast.2020.01.034.
Epub 2020 Jan 27. PMID: 32028173

7. Buonerba C, Ferro M, Dolce P, Crocetto F, Verde A, Lucarelli G, Scafuri L, Facchini S, Vaia A, Marinelli A, Terracciano D, Montella L, Longo N, Imbimbo C, Mirone V, Di Lorenzo G, De Placido S, Sonpavde G.
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Crit Rev Oncol Hematol. 2020 Jul; 151:102992.
doi: 10.1016/j.critrevonc.2020.102992. Epub 2020 May 23.
PMID:32474391

8. Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G.
Oncological care organisation during COVID-19 outbreak.
ESMO Open. 2020 Aug;5(4): e000853.
doi: 10.1136/esmoopen-2020-000853. PMID: 32847836

9. Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassinetti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, Petrelli F.
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.
Ther Adv Med Oncol. 2020 Jan 20; 12:1758835919899850.
doi: 10.1177/1758835919899850. eCollection 2020. PMID: 32010236

10. Caputo R, Cazzaniga ME, Sbrana A, Torrisi R, Paris I, Giordano M, Montesarchio V, Guarneri V, Amaducci L, Bilancia D, Cilenti G, Fabi A, Collovà E, Schirone A, Bonizzoni E, Celio L, De Placido S, De Laurentiis M.

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
 BMC Cancer. 2020 Mar 19;20(1):232.
 doi: 10.1186/s12885-020-6707-9. PMID: 32188417

11. De Placido S, Bracale U, Pacelli R, Sodo M, Merola G, Silvestri V, Corcione F.
 A New Strategy for a High Tumour Burden Region: The Campania Oncological Network.
 Transl Med UniSa. 2020 Feb 20; 21:59-60. eCollection 2020 Jan- Apr.
 PMID: 32123684 Free PMC article.

12. Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, De Laurentiis M, De Placido P, Rea CG, Pacilio C, Esposito E, Grimaldi M, Nocerino F, Porciello G, Giudice A, Amore A, Minopoli A, Botti G, De Placido S, Trivedi MV, Arpino G.
 Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
 Breast Cancer Res Treat. 2020 Jul;182(2):401-409.
 doi: 10.1007/s10549-020-05701-7. Epub 2020 Jun 4. PMID: 32500397
 Free PMC article.

13. Piccirillo MC, Avallone A, Carlomagno C, Maiello E, Rosati G, Alabiso O, Nasti G, De Placido S, Latiano TP, Bilancia D, Ottaiano A, De Stefano A, Romano C, Silvestro L, Nappi A, Cassata A, Giordano P, Iaffaioli RV, Normanno N, Perrone F, Daniele B.
 Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial.
 Clin Colorectal Cancer. 2020 May 29; S1533-0028(20)30082-7.
 doi: 10.1016/j.clcc.2020.05.009. Online ahead of print. PMID: 32631788

14. Conte B, Bruzzone M, Lambertini M, Poggio F, Bighin C, Blondeaux E, De Laurentiis M, Valle E, Cognetti F, Nisticò C, De Placido S, Garrone O, Gamucci T, Montemurro F, Puglisi F, Cardinali B, Fregatti P, Miglietta L, Boccardo F, Ceppi M, Del Mastro L; GIM2 Investigators.
 Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
 Eur J Cancer. 2020 Sep; 136:43-51.
 doi: 10.1016/j.ejca.2020.05.007. Epub 2020 Jul 4. PMID: 32634760

15. Nappi L, Ottaviano M, Rescigno P, Tortora M, Banna GL, Baciarello G, Basso U, Canil C, Cavo A, Cossu Rocca M, Czaykowski P, De Giorgi U, Garcia Del Muro X, Di Napoli M, Fornarini G, Gietema JA, Heng DY, Hotte SJ, Kollmannsberger C, Maruzzo M, Messina C, Morelli F, Mulder S, Nichols C, Nolè F, Oing C, Sava T, Secondino S, Simone G, Soulieres D, Vincenzi B, Zucali PA, De Placido S, Palmieri G; Italian Germ Cell Cancer Group (IGG); ERN-EURACAN Domain G3; Genitourinary Medical Oncologists of Canada (GUMOC).

Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers.

Oncologist. 2020 Jul 31.

doi: 10.1634/theoncologist.2020-0420. Online ahead of print. PMID: 32735386

16. Salvatore Del Prete, Liliana Montella, Grazia Arpino, Giuseppe Buono, Carlo Buonerba, Pasquale Dolce, Olga Fiorentino, Maria Aliberti, Antonio Febbraro, Clementina Savastano, Giuseppe Colantuoni, Ferdinando Riccardi, Angela Ruggiero, Sabino De Placido, Michele Orditura.

Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting

Oncotarget. 2020 Jun 2;11(22):2083-2091.

doi: 10.18632/oncotarget.27603. PMID: 32547706

PMCID: PMC7275781

17. Francesco Schettini, Irene De Santo, Carmen G Rea, Martina Viggiani, Giuseppe Buono, Carmine De Angelis, Cinzia Cardalesi, Rossella Lauria, Mario Giuliano, Valeria Forestieri, Guglielmo Thomas, Pierfrancesco Maione, Gennaro Limite, Antonello Accurso, Luca Malorni, Sabino De Placido, Grazia Arpino.

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series Mol Clin Oncol 2020 May;12(5):456-460.

doi: 10.3892/mco.2020.2016. Epub 2020 Mar 11.

PMID: 32257203 PMCID: PMC7087462

18. Biganzoli L, Cinieri S, Berardi R, Pedersini R, McCartney A, Minisini AM, Caremoli ER, Spazzapan S, Magnolfi E, Brunello A, Risi E, Palumbo R, Leo S, Colleoni M, Donati S, De Placido S, Orlando L, Pistelli M, Parolin V, Mislang A, Becheri D, Puglisi F, Sanna G, Zafarana E, Boni L, Mottino G. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.

Breast Cancer Res. 2020 Aug 5;22(1):83.

doi: 10.1186/s13058-020-01319-1. PMID: 32758299

19. Arpino G, De Angelis C, De Placido P, Pietroluongo E, Formisano L, Bianco R, Fiore G, Montella E, Forestieri V, Lauria R, Cardalesi C, Vozzella EA, Iervolino A, Giuliano M, De Placido S.

Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era.

ESMO Open. 2020 Sep;5(5): e000885. doi: 10.1136/esmoopen-2020-000885. PMID: 32958531

2019

20. Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S.

Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.

Ann Nucl Med. 2019 Oct 14.

doi: 10.1007/s12149-019-01407-z. [Epub ahead of print] PubMed PMID: 31612416.

21. Ottaviano M, Maddalena C, D'Armiento M, Lauria R, D'Alessandro V, Tortora M, Matano E, Di Lauro V, Mucci B, Ferraro G, De Placido S, Giuliano M, Palmieri G.

Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour.

Anticancer Drugs. 2019 Oct; 30(9):959-963.

doi: 10.1097/CAD.0000000000000806. PubMed PMID: 31517734.

22. Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, DeLaurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D.

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.

Lancet Oncol. 2019 Oct; 20(10):1360-1369.

doi:10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4. PubMed PMID: 31494037.

23. Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G.

Predictors of Outcomes in Patients with EGFR Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019 Aug 28;11(9). pii: E1259.

doi: 10.3390/cancers11091259. Review. PubMed PMID:

31466227; PubMed Central PMCID: PMC6770537.

24. Conforti A, Schettini F, Vallone R, Di Rella F, De Rosa P, De Santo I, Giuliano M, Arpino G, Lauria R, De Placido S, Caputo R, De Laurentiis M, Nazzaro G, De Placido G, Locci M, Alviggi C.

Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues.

Breast J. 2019 Nov; 25(6):1310-1311.

doi: 10.1111/tbj.13474. Epub 2019 Jul 23. PubMed PMID: 31338934.

25. Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R.

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.

Cancers (Basel). 2019 Jul 13; 11(7). pii: E981.

doi: 10.3390/cancers11070981. PubMed PMID: 31337045; PubMed Central PMCID: PMC6678351.

26. Santoro C, Esposito R, Lembo M, Sorrentino R, De Santo I, Luciano F, Casciano O, Giuliano M, De Placido S, Trimarco B, Lancellotti P, Arpino G, Galderisi M.
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction.
Eur Heart J Cardiovasc Imaging. 2019 Jul 21. pii: jez194.
doi: 10.1093/ehjci/jez194. [Epub ahead of print] PubMed PMID: 31326981.

27. Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, DiRella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C.
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Eur J Cancer. 2019 Sep; 118:178-186.
doi:10.1016/j.ejca.2019.05.004. Epub 2019 Jun 1. PubMed PMID: 31164265.

28. Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; "Metronomic Chemotherapy in Advanced Breast Cancer" Study Group.
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
Onco Targets Ther. 2019 Apr 23; 12:2989-2997.
doi: 10.2147/OTT.S189163. eCollection 2019. PubMed PMID: 31114242; PubMed Central PMCID: PMC6485034.

29. Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S.
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Gynecol Oncol. 2019 Jul; 154(1):83-88.
doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24. PubMed PMID: 31029508.

30. Ottaviano M, De Placido S, Ascierto PA.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Virchows Arch. 2019 Apr; 474(4):421-432.
doi: 10.1007/s00428-019-02538-4. Epub 2019 Feb 12. Review. PubMed PMID: 30747264.

31. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet*. 2019 Apr 6; 393(10179):1440-1452.
doi:10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8. PubMed PMID: 30739743; PubMedCentral PMCID: PMC6451189.

32. Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M, Corvaja C, Arpino G, Del Mastro L, De Placido S, De Laurentiis M, Cristofanilli M, Puglisi F.
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Cancer Treat Rev. 2019 Feb; 73:73-83.
doi:10.1016/j.ctrv.2019.01.004. Epub 2019 Jan 11. Review.
PubMed PMID: 30682661.

2018

33. Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, Del Mastro L.
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.
Front Oncol. 2018 Dec 12; 8:608.
doi: 10.3389/fonc.2018.00608. eCollection 2018. Review. PubMed PMID: 30631751; PubMed Central PMCID: PMC6315195.
34. Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassinetti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators.
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Oncologist. 2019 Mar; 24(3):385-393.
doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3. PubMed PMID: 30606884; PubMed Central PMCID: PMC6519752.
35. Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med. 2019 Feb 14; 380(7):617-628.
doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PubMed PMID: 30516102.

36. Montanari M, Carbone MR, Coppola L, Giuliano M, Arpino G, Lauria R, Nardone A, Leccia F, Trivedi MV, Garbi C, Bianco R, Avvedimento EV, De Placido S, Veneziani BM.
Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44(+)/CD24(low)/CD90(+) Myoepithelial Cells.
Mol Cancer Res. 2019 Feb; 17(2):628-641.
doi:10.1158/1541-7786. MCR-17-0324. Epub 2018 Sep 21. PubMed PMID: 30242055.

37. Riccardi F, Colantuoni G, Diana A, Mocerino C, Cartenì G, Lauria R, Febbraro A, Nuzzo F, Addeo R, Marano O, Incoronato P, De Placido S, Ciardiello F, Orditura M.
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.
Mol Clin Oncol. 2018 Sep; 9(3):255-263.
doi: 10.3892/mco.2018.1672. Epub 2018 Jul 16. PubMed PMID: 30155246; PubMed Central PMCID: PMC6109668.

38. Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G; PERTAIN Study Group.
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
J Clin Oncol. 2018 Oct 1; 36(28):2826-2835.
doi: 10.1200/JCO.2017.76.7863. Epub 2018 Aug 14. PubMed PMID: 30106636.

39. Carlomagno C, De Stefano A, Rosanova M, De Falco S, Attademo L, Fiore G, De Placido S.
Multiple treatment lines and prognosis in metastatic colorectal cancer patients.
Cancer Metastasis Rev. 2019 Jun; 38(1-2):307-313.
doi: 10.1007/s10555-018-9748-7. Review. PubMed PMID: 30003458.

40. Marinelli A, Lamberti G, Cerbone L, Cordua N, Buonerba C, Peluso G, Di Lorenzo G, De Placido S.
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Medicine (Baltimore). 2018 Jul; 97(27): e11254.
doi: 10.1097/MD.00000000000011254. PubMed PMID: 29979390; PubMed Central PMCID: PMC6076126.

41. De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
 BJU Int. 2019 Jan; 123(1):98-105.
 doi:10.1111/bju.14461. Epub 2018 Jul 23. PubMed PMID: 29956884.

42. Condello C, Rescigno P, Ottaviano M, Nappi L, Tortora M, de Placido S, Palmieri G.
 Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors.
 Future Oncol. 2018 Jul; 14(16):1591-1599.
 doi: 10.2217/fon-2017-0670. Epub 2018 Jun 29. Review. PubMed PMID: 29956548.

43. Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G.
 Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
 Cancer Treat Rev. 2018 Jul; 68:102-110.
 doi:10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11. Review. PubMed PMID: 29940524.

44. Nappi L, Ottaviano M, Rescigno P, Fazli L, Gleave ME, Damiano V, De Placido S, Palmieri G.
 Long term deficiency of vitamin D in germ cell testicular cancer survivors.
 Oncotarget. 2018 Apr 20; 9(30):21078-21085.
 doi:10.18632/oncotarget.24925. eCollection 2018 Apr 20. PubMed PMID: 29765521; PubMed Central PMCID: PMC5940414.

45. Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.
 Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.
 Oncotarget. 2018 Apr 13; 9(28):19861-19873.
 doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13. PubMed PMID: 29731989; PubMed Central PMCID: PMC5929432.

46. Buonerba C, De Placido P, Bruzzese D, Pagliuca M, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, Romeo V, Izzo M, Perri F, Casale B, Grimaldi G, Vitrone F, Brunetti A, Terracciano D, Marinelli A, De Placido S, Di Lorenzo G.
 Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial.
 Front Pharmacol. 2018 Mar 16; 9: 189.
 doi: 10.3389/fphar.2018.00189. eCollection 2018. PubMed PMID: 29615901; PubMed Central PMCID: PMC5864863.

47. De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moschetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.
Adjuvant anastrozole versus xemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol. 2018 Apr; 19(4):474-485.
doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr; 19(4):e184. PubMed PMID: 29482983.
48. Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV.
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize.
Cancer Res. 2018 Feb 15; 78 (4):845-852.
doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2. PubMed PMID: 29437766.
49. Pensabene M, Stanzone B, Cerillo I, Ciancia G, Cozzolino I, Ruocco R, Condello C, Di Lorenzo G, Giuliano M, Forestieri V, Arpino G, De Placido S, Lauria R.
It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.
BMC Cancer. 2018 Feb 6; 18(1):146.
doi: 10.1186/s12885-018-4054-x. Review. PubMed PMID: 29409458; PubMed Central PMCID: PMC5801832.

2017

50. Buonerba C, Sonpavde G, Vitrone F, Bosso D, Puglia L, Izzo M, Iaccarino S, Scafuri L, Muratore M, Foschini F, Mucci B, Tortora V, Pagliuca M, Ribera D, Riccio V, Morra R, Mosca M, Cesarano N, Di Costanzo I, De Placido S, Di Lorenzo G.
The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
J Cancer. 2017 Aug 22; 8(14):2663-2668.
doi: 10.7150/jca.20040. eCollection 2017. PubMed PMID: 28928853; PubMed Central PMCID: PMC5604196.
51. Buonerba C, Pagliuca M, Vitrone FM, Ascione I, Elefante I, Riccio V, Romano F, De Placido S, Di Lorenzo G.
Immunotherapy for penile cancer.
Future Sci OA. 2017 May 2;3(3):FSO195.
doi: 10.4155/fsoa-2017-0031. eCollection 2017 Aug. PubMed PMID: 28883996; PubMed Central PMCID: PMC5583688.

52. Di Lorenzo G, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Federico P, Daniele B, Morelli F, Bellelli T, Ferro M, De Placido S, Buonerba C.
Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate.
Eur Urol Focus. 2017 Apr 8. pii: S2405-4569(17)300834.
doi:10.1016/j.euf.2017.03.015.
[Epub ahead of print] PubMed PMID: 28753882.

53. De Stefano A, Rosanova M, Malapelle U, Martini M, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C.
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?
Int J Biol Markers. 2017 Jun 20:0.
doi: 10.5301/ijbm.5000273. [Epub ahead of print] PubMed PMID: 28665451.

54. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Eur J Cancer. 2017 Sep; 82: 237-246.
doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. PubMed PMID: 28625777.

55. Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.
Medicine (Baltimore). 2017 Jun;96(24): e6817.
doi: 10.1097/MD.0000000000006817. PubMed PMID: 28614217;
PubMed Central PMCID: PMC5478302.

56. Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, Bruzzese D, De Placido S, Arpino G.
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study.
Clin Breast Cancer. 2017 May 19. pii: S1526-8209(17)30168-4.
doi: 10.1016/j.clbc.2017.05.007. [Epub ahead of print] PubMed PMID: 28601383.

57. Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Br J Cancer. 2017 May 23; 116(11):1425-1435.

doi: 10.1038/bjc.2017.116. Epub 2017 Apr 25. PubMed PMID: 28441382; PubMed Central PMCID: PMC5520095.

58. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med. 2017 Jul 13; 377(2):122-131.
doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17; 377(7):702. PubMed PMID: 28581356; PubMed Central PMCID: PMC5538020.
59. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.
Oncologist. 2017 May; 22(5):601-608.
doi: 10.1634/theoncologist.2016-0246. Epub 2017 Apr 19. PubMed PMID: 28424324; PubMed Central PMCID: PMC5423517.
60. Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, de Simone G, Trimarco B, De Placido S, Galderisi M.
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.
Eur Heart J Cardiovasc Imaging. 2017 May 1; 18(8):930-936.
doi:10.1093/ehjci/jex033. PubMed PMID: 28379383.
61. Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, Khoo V, Hakenberg OW, Draeger D, Protzel C, Heidenreich A, Haidl F, Eigl BJ, Nappi L, Matsumoto K, Vaishampayan U, Woods ME, Salvioni R, Nicolai N, Catanzaro M, Giannatempo P, Geynisman DM, Preto M, Xylinas E, Milowsky MI, De Placido S, Di Lorenzo G, Sonpavde G.
Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.
Clin Genitourin Cancer. 2017 Oct; 15(5):548-555.e3.
doi: 10.1016/j.clgc.2017.02.002. Epub 2017 Feb 27. PubMed PMID: 28325636.
62. De Placido S, De Angelis C, Giuliano M, Pizzi C, Ruocco R, Perrone V, Bruzzese D, Tommasielli G, De Laurentiis M, Cammarota S, Arpino G, Arpino G.
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
Br J Cancer. 2017 Mar 14; 116(6):821-827.
doi: 10.1038/bjc.2017.24. Epub 2017 Feb 7. PubMed PMID: 28170371; PubMed Central PMCID: PMC5355929.

63. Buonerba C, Di Lorenzo G, Pond G, Cartenì G, Scagliarini S, Rozzi A, Quevedo FJ, Dorff T, Nappi L, Lanzetta G, Pagliaro L, Eigl BJ, Naik G, Ferro M, Galdiero M, De Placido S, Sonpavde G.
Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.
Front Pharmacol. 2016 Dec 20; 7:487.
doi: 10.3389/fphar.2016.00487. eCollection 2016. PubMed PMID: 28066240; PubMed Central PMCID: PMC5168461.
64. Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Eur J Cancer. 2017 Jan; 71:34-42.
doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10. PubMed PMID: 27951450.
65. Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S.
Tumor characteristics and prognosis in familial breast cancer.
BMC Cancer. 2016 Nov 29; 16(1):924. PubMed PMID: 27899083; PubMed Central PMCID: PMC5129604.
66. Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F.
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.
Breast. 2017 Feb; 31: 114-120.
doi: 10.1016/j.breast.2016.10.021. Epub 2016 Nov 9. PubMed PMID: 27837704.
67. Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Ann Oncol. 2016 Nov; 27(11):2074-2081. Epub 2016 Aug 29. PubMed PMID: 27573560.
68. Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani

BM, De Placido S, Bianco R. Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.
 Oncotarget. 2016 Jun 28;7(26):40073-40084.
 doi: 10.18632/oncotarget.9484. PubMed PMID: 27223077; PubMed Central PMCID: PMC5129993.

69. Rosa R, D'Amato V, De Placido S, Bianco R.
 Approaches for targeting cancer stem cells drug resistance.
 Expert Opin Drug Discov. 2016 Dec; 11(12):1201-1212. Epub 2016 Oct 14. Review. PubMed PMID: 27700193.
70. Schettini F, Giuliano M, De Placido S, Arpino G.
 Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
 Cancer Treat Rev. 2016 Nov; 50:129-141.
 doi: 10.1016/j.ctrv.2016.09.004. Epub 2016 Sep 12. Review. PubMed PMID: 27665540.
71. Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, De Placido S, Nazzaro G, Locci M, De Placido G.
 Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
 Menopause. 2016 Oct;23(10):1108-13.
 doi: 10.1097/GME.0000000000000672. PubMed PMID: 27648595.

2015

72. Ferro M, Terracciano D, Buonerba C, Lucarelli G, Bottero D, Perdonà S, Autorino R, Serino A, Cantiello F, Damiano R, Andras I, De Placido S, Di Lorenzo G, Battaglia M, Jereczek-Fossa BA, Mirone V, De Cobelli O. The emerging role of obesity, diet and lipid metabolism in prostate cancer.
 Future Oncol. 2017 Feb;13(3):285-293.
 doi: 10.2217/fon-2016-0217. Epub 2016 Sep 14. Review. PubMed PMID: 27624840; PubMed Central PMCID: PMC5619099.
73. Pensabene M, Condello C, Carlomagno C, De Placido S, Liccardo R, Duraturo F.
 Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer. Hered Cancer Clin Pract. 2016 Sep 6;14(1):18.
 doi: 10.1186/s13053-016-0054-5. eCollection 2016. PubMed PMID: 27602174; PubMed Central PMCID: PMC5011803.
74. Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G.
 The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.
 Expert Opin Biol Ther. 2016 Nov; 16(11):1387-1401. Epub 2016 Aug 5. PubMed PMID: 27463642.

75. Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.
Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
BMC Cancer. 2016 Jul 4; 16:375.
doi: 10.1186/s12885-016-2414-y. PubMed PMID: 27377827; PubMed Central PMCID: PMC4932666.
76. Crispo A, Montella M, Buono G, Grimaldi M, D'Aiuto M, Capasso I, Esposito E, Amore A, Nocerino F, Augustin LS, Giudice A, Di Bonito M, Giuliano M, Forestieri V, De Laurentiis M, Rinaldo M, Ciliberto G, De Placido S, Arpino G.
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
Curr Res Transl Med. 2016 Jan-Mar; 64(1):15-20.
doi: 10.1016/j.retram.2016.01.004. Epub 2016 Mar 2. PubMed PMID: 27140595.
77. Di Lorenzo G, Pagliuca M, Perillo T, Benincasa A, Bosso D, De Placido S, Buonerba C.
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.
Medicine (Baltimore). 2016 Apr;95(14):e2754.
doi: 10.1097/MD.0000000000002754. Review. PubMed PMID: 27057826; PubMed Central PMCID: PMC4998742.
78. Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L.
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Cancer Treat Rev. 2016 May; 46:20-6.
doi: 10.1016/j.ctrv.2016.03.012. Epub 2016 Apr 1. Review. PubMed PMID: 27057657.
79. Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.
Mol Cancer Res. 2016 May;14(5):470-81.
doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10. PubMed PMID: 26965145; PubMed Central PMCID: PMC4867274.
80. 61: Di Lorenzo G, Pagliuca M, Perillo T, Zarrella A, Verde A, De Placido S, Buonerba C.
Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report.
Medicine (Baltimore). 2016 Feb; 95(5):e2598.
doi:10.1097/MD.0000000000002598. PubMed PMID: 26844468; PubMed Central PMCID: PMC4748885.

81. Ferro M, Buonerba C, Terracciano D, Lucarelli G, Cosimato V, Bottero D, Deliu VM, Ditunno P, Perdonà S, Autorino R, Coman I, De Placido S, Di Lorenzo G, De Cobelli O.
Biomarkers in localized prostate cancer.
Future Oncol. 2016 Feb;12(3):399-411. doi: 10.2217/fon.15.318. Epub 2016 Jan 15. Review. PubMed PMID: 26768791; PubMed Central PMCID: PMC5549774.

82. Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, De Placido S, Bonaduce D, Tocchetti CG.
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.
Biomed Res Int. 2015; 2015:138148.
doi: 10.1155/2015/138148. Epub 2015 Oct 25. Review. PubMed PMID: 26583088; PubMed Central PMCID: PMC4637019.

83. Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, Giglio A, Cagiano S, Bufo P, Maiorano E, Ribatti D, Ranieri E, Gigante M, Gesualdo L, Ferro M, de Cobelli O, Buonerba C, Di Lorenzo G, De Placido S, Palazzo S, Bettocchi C, Ditunno P, Battaglia M.
Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.
Medicine (Baltimore). 2015 Nov;94(46):e2117.
doi: 10.1097/MD.0000000000002117. PubMed PMID: 26579829; PubMed Central PMCID: PMC4652838.

84. Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.
J Cancer Res Clin Oncol. 2016 Mar; 142(3):669-78.
doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25. PubMed PMID: 26531187.

85. Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M, Borghesi M, De Berardinis E, Busetto GM, Giovannone R, Lucarelli G, Ditunno P, Perdonà S, Bove P, Castaldo L, Hurle R, Musi G, Brescia A, Olivieri M, Cimmino A, Altieri V, Damiano R, Cantiello F, Serretta V, De Placido S, Mirone V, Sonpavde G, Terracciano D.
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.
Medicine (Baltimore). 2015 Oct;94(42): e1861.
doi: 10.1097/MD.0000000000001861. PubMed PMID: 26496339; PubMed Central PMCID: PMC4620818.

86. D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R.
Mechanisms of lapatinib resistance in HER2-driven breast cancer.

Cancer Treat Rev. 2015 Dec; 41(10):877-83.
doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Review. PubMed
PMID: 26276735.

87. Di Lorenzo G, Bracarda S, Gasparro D, Gernone A, Messina C, Zagonel V, Puglia L, Bosso D, Dondi D, Sonpavde G, Lucarelli G, De Placido S, Buonerba C.
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Medicine (Baltimore). 2016 Jan;95(2):e2299.
doi: 10.1097/MD.0000000000002299. PubMed PMID: 26765406;
PubMed Central PMCID: PMC4718232.
88. Di Lorenzo G, Buonerba C, Bellelli T, Romano C, Montanaro V, Ferro M, Benincasa A, Ribera D, Lucarelli G, De Cobelli O, Sonpavde G, De Placido S.
Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.
Medicine (Baltimore). 2015 Dec;94(51):e2297.
doi: 10.1097/MD.0000000000002297. PubMed PMID: 26705213;
PubMed Central PMCID: PMC4697979.
89. Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, Limite G, Lauria R, Veneziani BM, Forestieri V, Bruzzese D, De Placido S.
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy.
Breast Cancer Res Treat. 2015 Nov; 154(1):127-32.
doi: 10.1007/s10549-015-3586-x. Epub 2015 Sep 30. PMID:26424165.
90. Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, Giglio A, Cagiano S, Bufo P, Maiorano E, Ribatti D, Ranieri E, Gigante M, Gesualdo L, Ferro M, de Cobelli O, Buonerba C, Di Lorenzo G, De Placido S, Palazzo S, Bettocchi C, Ditunno P, Battaglia M.
Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.
Medicine (Baltimore). 2015 Nov;94(46): e2117.
Doi: 10.1097/MD.0000000000002117.
91. Criscitiello C, Esposito A, De Placido S, Curigliano G.
Targeting fibroblast growth factor receptor pathway in breast cancer.
Curr Opin Oncol. 2015 Nov;27(6):452-6.
Doi: 10.1097/CCO.000000000000224. PMID: 26397764.
92. De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, Ferro M.
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.
Future Oncol. 2015 Nov;11(22):3091-8.
doi: 10.2217/fon.15.249. Epub 2015 Sep 18.

93. Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, De Placido S, Bonaduce D, Tocchetti CG.
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.
Biomed Res Int. 2015; 2015:1 38148.
doi: 10.1155/2015/138148. Epub 2015 Oct 25. Review.PMID: 26583088.

94. Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M.
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Eur J Surg Oncol. 2015 Oct; 41(10):1288-92.
doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Review.PMID: 26238477

95. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, [...] De Placido S, [...] Gray R.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Lancet. 2015 Oct 3; 386(10001):1341-52.
doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23. PMID: 26211827.

96. De Feo G, Frontini L, Rota S, Pepe A, Signoriello S, Labianca R, Sobrero A, De Placido S, Perrone F.
Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research.
J Med Ethics. 2015 Oct; 41(10):799-803.
doi: 10.1136/medethics-2012-100803. Epub 2015 Jun 11. PMID: 26066362.

97. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, [...] De Placido S, Gray R.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Lancet. 2015 Oct 3; 386(10001):1353-61.
doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23.
PMID: 26211824.

98. Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Oncotarget. 2015 Sep 22; 6(28):26090-103.
doi: 10.18632/oncotarget.4636. PMID: 26325669.

99. Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.
J Cancer Res Clin Oncol. 2015 Aug 25. PMID: 26531187.

100. Di Lorenzo G, Federico P, De Placido S, Buonerba C.
Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review.
Crit Rev Oncol Hematol. 2015 Jul 20. pii: S1040-8428(15)30004-4.
doi: 10.1016/j.critrevonc.2015.07.004. [Epub ahead of print]
Review. PMID: 26520458.
101. Del Mastro L, Cazzaniga M, Solidoro P, Generali D, Bianchi G, Testore F, De Placido S.
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.
Future Oncol. 2015;11(16):2251-4.
doi: 10.2217/fon.15.134. PMID: 26260802.
102. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lancet. 2015 May 9; 385(9980):1863-72.
doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2. PMID: 25740286.
103. Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A.
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Ann Oncol. 2015 Apr;26(4):675-82.
doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8. PMID: 25488686.
104. Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F.
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
J Clin Oncol. 2015 Mar 10;33(8):910-5.
doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26. PMID: 25624439.
105. Di Lorenzo G, Buonerba C, De Placido S.

Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation.
 Anticancer Drugs. 2015 Feb;26(2):236-9.
 doi: 10.1097/CAD. PMID:25340916.

106. Arpino G, De Placido S, De Angelis C.
 Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study.
 Anticancer Drugs. 2015 Jan; 26(1):117-22.
 doi: 10.1097/CAD. PMID:25115342.

107. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutati V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIg) Investigators.
 Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
 Lancet. Apr; 15(4):396-405.
 doi: 10.1016/S1470-2045(14)70049-X. 2014

2014

108. Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G.
 Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment.
 Cancer Treat Rev. 2014 Dec 8. S0305-7372(14)00193-5.
 doi: 10.1016/j.ctrv.2014.12.001.

109. De Stefano A, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Di Pietro F, Pepe S, De Placido S, Carlomagno C.
 Bevacizumab maintenance in metastatic colorectal cancer: How long?
 World J Clin Cases. 2014 Nov 16;2(11):717-23.
 doi:10.12998/wjcc.v2.i11.717. PMID:25405197 IF No

110. De Placido S, Pronzato P.
 Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?
 Future Oncol. 2014 Sep 18:1-7.
 PMID:25230682.

111. D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R.
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. *Br J Cancer*. 2014 Sep 9;111(6):1168-7
doi: 10.1038/bjc.2014.421.
112. De Placido S, Rescigno P, Federico P, Buonerba C, Bosso D, Puglia L, Izzo M, Policastro T, Di Lorenzo G.
Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.
World J Clin Cases. 2014 Jun 16; 2(6):228-31
doi:10.12998/wjcc.v2.i6.228. PMID: 24945013.
113. Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G.
Dendritic cell-based vaccines: clinical applications in breast cancer.
Immunotherapy.
2014 Mar;6(3):349-60.
doi: 10.2217/imt.13.169.PMID:24762078.
114. Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Ann Oncol. 2014 Jul;25(7):1373-8.
doi: 10.1093/annonc/mdu146.
115. Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D.
Targeting bone metastatic cancer: Role of the mTOR pathway.
Biochim Biophys Acta. 2014 Apr; 1845(2):248-54.
doi: 10.1016/j.bbcan.2014.01.009.
116. Di Lorenzo G, De Placido S.
Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?
Future Oncol. 2014 Apr;10(5):845-50
doi: 10.2217/fon.13.269.
117. Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, Troncone G, De Stefano A, Pepe S, De Placido S, D'Incalci M, Marchini S, Carlomagno C.
Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients.

Biomed Res Int. 2014; 2014:840921.
doi: 10.1155/2014/840921.

118. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.
Breast Cancer Res. 2014 Sep 16; 16(5):440.
doi: 10.1186/s13058-014-0440-8. PMID:25223629.
119. Formisano L, Nappi I, Rosa R, Marciano R, D'Amato C, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R.
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Breast Cancer Res. 2014 May 5;16(3):R45.
doi: 10.1186/bcr3650.
120. Buonerba C, Federico P, Bosso D, Puglia L, Policastro T, Izzo M, Perri F, Vittoria Scarpato GD, Ferro M, Cobelli OD, De Placido S, Aieta M, Imbimbo C, Di Lorenzo G.
Carboplatin plus etoposide in heavily pretreated castration- resistant prostate cancer patients.
Future Oncol.2014 Jun;10(8):1353-60.
doi: 10.2217/fon.14.71. PMID: 25052746.
121. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
Lancet. Jun 21;383(9935):2127-35;
doi: 10.1016/S0140-6736(14)60488-8.
122. Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G.
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Breast. 2014 Feb;23(1):69-75.
doi: 10.1016/j.breast.2013.11.007. PMID: 24314620 IF 2.381
123. D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R.
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
Br J Cancer. 2014 Jun 10; 110(12):2887-95.
doi: 10.1038/bjc.2014.241. 2013

124. De Stefano A, Moretto R, Bucci L, Pepe S, Romano FJ, Cella AC, Attademo L, Rosanova M, De Falco S, Fiore G, Raimondo L, De Placido S, Carlomagno C.
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when and for whom?
Clinical Colorectal Cancer; Sep;13(3):185-91.
125. Pizzi C, Arpino G, Acampora G, Aiello N, DE Rosa A, Diaferia I, DI Nunzio A, Fragna G, Franco A, Russo M, Sansone F, Scarpati C, Spinuso A, Arpino G, Luce A, Tommasielli G, Caraglia M, DE Placido S.
Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network.
Mol Clin Oncol. 726-732. PMID:24649236 IF No
126. De Angelis C, Milano M, Gargiulo P, Stanzione B, Forestieri V, Lauria R, Pensabene M, D'Arco F, De Placido S, Arpino G.
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.
Tumori. doi: 10.1700/1334.14822.PMID:24158083.
127. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M.
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.
Biomed Res Int.
doi: 10.1155/2013/852839. Review.PMID:24063014.
128. Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L.
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study. Gruppo Italiano Mammella.
Oncologist.
doi: 10.1634/theoncologist.2013-0222. PMID: 23939283.
129. Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudioso G, Terracciano D, Di Trollo R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA, Franco R.J
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study.
Transl Med.
doi: 10.1186/1479-5876-11-161.PMID:23819610.
130. Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G.
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
Future Oncol. doi: 10.2217/fon.13.39.PMID:23718309.

131. Rescigno P, Di Trollo R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G.
Non-AIDS-related Kaposi's sarcoma: A single-institution experience.
World J Clin Oncol.doi: 10.5306/wjco.v4.i2.52.PMID:23696963.
132. Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L.
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Breast 2013. doi: 10.1016/j.breast.2013.03.012. Epub 2013 May 1.PMID:23642526.
133. Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cignetti F.
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
BMC Cancer. doi: 10.1186/1471-2407-13-164.PMID:23537313.
134. Di Lorenzo G, Buonerba C, Gaudioso G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trollo R, Ascierto PA, De Placido S, Perdonà S, Franco R.
EGFR mutational status in penile cancer.
Expert Opin Ther Targets.
doi: 10.1517/14728222.2013.783571.PMID:23517177.
135. Di Lorenzo G, D'Aniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S.
Peg-filgrastim and cabazitaxel in prostate cancer patients.
Anticancer Drugs.
doi: 10.1097/CAD.0b013e32835a56bc. PMID:23044721.
136. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutati V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIg) Investigators.
Lancet Oncol. 2014 Apr;15(4):396-405.
doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28.
137. Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R.

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.
Oncoimmunology, vol. 2

138. De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, pace L, De Placido S, Salvatore M, Del Vecchio S.
Combined Imaging With 18F-FDG-PET/CT and 111 In-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors.
Clinical Nuclear Medicine
139. Clavarezza M, Bordinaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, De Mastrol L; Gruppo Italiano Mammella.
Oncologist, vol. 18, pag. 924-25.
140. Moretto R, Raimondo L, De Stefano A, Cella CA, Matano E, De Placido S, Carlomagno C.
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Anticancer Drugs, vol. 24, pag. 980-5.
141. Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G.
Potentia value of Gleason scoere in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
Future Oncology, vol. 9, pag, 889-97.
142. Gentile I, De Stefano A, Di Flumeri G, Buonomo AR, Carlomagno C, Morisco F, De Placido S, Borgia G.
Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a cae report.
In Vivo, vol, 27, pag. 527-9.
143. Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.
An Italian cost- effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional pacliatxel for metastatic breast cancer patients: the COSTANza study.
Clinicoeconomics Outcomes Research IF No
144. Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, veneziani BM, De Placido S, Bianco R, Tortora G.
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumor growth and angiogenesis.
British Journal Cancer, vol. 108, pag. 1616-23.
145. Arpino G, Generali D, Sapino A, Lucia DM, Frassoldati A, De Laurentiis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L.
Gene expression profiling in breast cancer: A clinical perspective.

Breast

146. Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, Bianca D, De Placido S, Ayala F.
EMPACT syndrome associated with phenobarbital.
Dermatitis, vol. 24, pag. 37-39.
147. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, veneziani BM, Troncone G, De Placido S, Bianco R.
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Clinical Cancer Research, vol. 19, pag. 138-147.

2012

148. Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G.
New perspectives in the therapy of castration resistant prostate cancer.
Curr Drug Targets. Review.PMID:23043326.
149. Malgieri S, Feliciano S, Bosso D, Federico P, Palmieri G, De Placido S, Di Lorenzo G, Buonerba C.
Non-small cell lung cancer: from targeted therapy to tailored therapy.
Expert Opin Pharmacother. 2012 Sep;13(13):1817-9.
doi: 10.1517/14656566.2012.707645.PMID:2280370.
150. Di Lorenzo G, De Placido S, Buonerba C. Second-line treatment for renal cell cancer.
Br J Cancer. doi: 10.1038/bjc.2011.611. PMID:22333706.
151. Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S.
Cisplatin and 5-fluorouracil in inoperable stage IV squamous cell carcinoma of the penis.
BJU International
152. Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, Marciano R, Cimminiello C, Bellevicine C, De Placido S, Troncone G. (in stampa).
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer.
British Journal of Cancer, pag. 1-6.
153. Della Vittoria Scarpati G, Falchetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh Vijay K, D'Incalci M, De Placido S, Pepe S.

A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer.

International Journal of Radiation Oncology Biology Physics, vol. 83, pag. 1113-1119.

154. Grünwald V., Karakiewicz P.I, Bavbek S.E, Miller K., Machiels J.P., Lee S.H., Larkin J., Bono P., Rha S.Y., Castellano D., Blank C.U., Knox J.J., Hawkins R., Anak O., Rosamilia M., Booth J., Pirotta N., Bodrogi I., REACT Study Group, included, De Placido S. (2012).

An international expanded-access programme of everolimus addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor tyrosine-kinase inhibitor therapy.

European Journal of Cancer, p. 324-332, ISSN: 0959-8049.

155. Rescigno P., Matano E., Raimondo L., Mainolfi C., Fedele P., Buonerba C., Di Trollo R., D'Aniello C., Damiano V., Palmieri G., De Placido S., Di Lorenzo G. (2012).

Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.

Anticancer Drugs, p. 573-577, ISSN: 0959-4973.

156. Leccia F, Nardone A, Corvigno S, Del Vecchio L, De Placido S, Salvatore F, Veneziani BM.

Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes.

Cytometry.

PART A, ISSN: 1552-4922, doi: 10.1002/cyto.a.22095.

157. Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, Caolo G, Mottolese M, Botti G, Terrenato I, Vici P, Serpico D, Giordano A, D'Aiuto G, Crispo A, Montella M, Capurso G, Delle Fave G, Fuhrman B, Botti C, De Placido S.

Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.

Annals of Oncology, vol. 23, pag. 1838-1845.

158. Veneziani BM., De Placido S.

Issues of banking breast cancer cells to generate mammospheres.

Cell and Tissue Banking, p. 1-6, ISSN: 1389-9333,

doi: 10.1007/s10561-012-9320-6.

2011

159. Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, De Placido S, Tortora G.

Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials.

Experimental and Therapeutic Medicine vol. 2, pag. 449-455.

160. Di Lorenzo G., Casciano R., Malangone E., Buonerba C., Sherman S., Willet J., Wang X., Liu Z., De Placido S.
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples .
Exper Opinion on Pharmacotherapy, pag. 1491-1497, ISSN: 1465-6566.

161. Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Puzsai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
Breast Cancer Research and Treatment, vol. 129, pag. 451-458.

162. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S.
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients.
Cancer Chemotherapy and Pharmacology, vol. 68, pag. 1207-1213.

163. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Breast Cancer Research, vol. 13, pag. R67-R76.

164. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M.
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Annals of Oncology, p. Epub ahead of print, ISSN: 0923-7534, doi: 10.1093/annonc/mdr434.

165. Airolli M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta M.T, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini C.A, Veronesi A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a syntetic review.
Tumori, pag. 690-692.

166. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S (2011).
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Lancet, vol. 378, p. 1707-171.

167. Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI, ATHENA Study Group, De Placido S.
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients
Annals of Oncology, pag. 595-60.
168. Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V.
Imatinib mesylate in thymic epithelial malignancies.
Cancer Chemotherapy and Pharmacology, pag. 309-31.
169. Campiglio M., Bufalino R., Sandri M., Ferri E., Aiello R.A., De Matteis A., Mottolese M., De Placido S., Querzoli P., Jirillo A., Bottini A., Fantini M., Bonetti A., Pedani F., Mauri M., Molino A., Ferro A., Pupa S.M., Sasso M., Ménard S., Balsari A., Tagliabue E.
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.
Breast Cancer Research and Treatment, pag. 147-154.
170. Adamo V, Ricciardi GR, De Placido S, Colucci G, Conte P, Giuffrida D, Gebbia N, Masci G, Cognetti F, Dondi D, Venturini M. Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience.
European Journal of Cancer, pag. 642-647.
171. Di Lorenzo G., Federico P., Buonerba C., Longo N., Cartenì G., Autorino R., Perdonà S., Ferro M., Rescigno P., D'Aniello C., Matano E., Altieri V., Palmieri G., Imbimbo C., De Placido S., Mirone V.
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
European Urology, pag. 1280-1284.
172. Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Cancer Chemotherapy and Pharmacology, pag. 1455-1461.
173. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Lancet. vol. 378, pag. 771-784.

174. Buonerba C, Di Lorenzo G, Marinelli A, Federico P., Palmieri G., Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH.
A comprehensive outlook on intracerebral therapy of malignant gliomas.
Critical Reviews in Oncology Hematology, vol. 80, pag. 54-68.
175. Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.
A third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
European Urology, vol. 58, pag. 906-911.
176. Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, Crispo A, Cannella L, De Stefano Alfonso, D'Armiento F P, De Placido S.
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors.
Experimental and Therapeutic Medicine, vol. 1, pag. 611-617.
177. Capri G, Chang J, Chen Sc, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schutte J, Oliva C, Parikh R, Preston A, Roselund J, Selzer M, Zembryki D, De Placido S (2010). An open-label expanded assessment study of lapatinib and capecitabine in patients with HER2 - overexpressing locally advanced or metastatic breast cancer.
Annals of Oncology, pag. 474-480.
178. Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A.
Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?
Journal of Neuro-Oncology, vol. 100, pag. 311-319.
179. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Strernberg CN.
Castration-resistant prostate cancer: current and emerging treatment strategies.
Drugs, pag. 983-1000.
180. Terracciano D, Mazzearella C, Di Carlo A, Mariano A, Ferro M, Di Lorenzo G, Giordano A, Altieri V, De Placido S, Macchia V.
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Oncology Reports, vol. 24, pag. 213-217.
181. Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Meroca MC, De Placido S, Palmieri G.
Efficacy of rituximab in gastric diffuse large B cell Lymphoma patients.
World Journal of Gastroenterology, pag. 2526-2530.

182. Colantuoni M, Matano E, Alfieri S, De Placido S, Carlomagno C. Guillain Barrè syndrome associated with gastric cancer: paraneoplastic syndrome or immunological disorder?
World Journal of Oncology, vol. 1, pag.247-249.
183. Carlomagno C, Insabato L, Bifulco G, De Placido S, Lauria R.
Ovarian metastasis following gallbladder carcinoma: a case report.European Journal of Gynaecological, pag. 219-221
184. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C., McGale P., Taylor C., Wang Y., Clarke M., Davies C., Peto R., Bijker N., Solin L., Darby S., De Placido S.
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Journal of the National Cancer, pag. 162-177.
185. Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G.
Phase II Study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.
BJU International, pag. 234-239.
186. Carlomagno C, Pepe S, D'Armiento FP, D'Armiento M, Cannella L, De Stefano A, Crispo A, Giordano M, De Placido S.
Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Oncology, vol. 78, pag.369-375.
187. Palmieri G, Merola G, Federico P, Petillo L, Marino M, Lalle M, Milella M, Ceribelli A, Montella L, Merola C, Del Prete S, Vergaglio M, De Placido S, Di Lorenzo G.
Preliminary result of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Annals of Oncology, pag. 1168-1172.
188. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Clack G, Bianco AR, ATAC Trialists' Group, De Placido S.
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Journal of Obstetrics and Gynaecology, pag. 596-604.
189. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S.
Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
Cancer Treatment Review, pag 80-86 2009.

2009

190. Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S.
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Anticancer Drugs, vol. Anti-cancer Drugs, pag. 277-280.
191. Nardone A, Cavaliere C, Corvigno, S, Limite G, De Placido S, Veneziani BM.
A banking strategy toward customized therapy in breast cancer.
Cell and Tissue Banking, vol. 10, pag. 301-308.
192. Di Lorenzo G, Autorino R, Bruni G, Cartenì G, Ricevuto E, Tadini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S.
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Annals of Oncology, pag. 1535-1542.
193. Montagna E, Canello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
Cancer Chemotherapy and Pharmacology, vol. 63, pag. 275-280.
194. Arpino G, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, De Placido S.
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer.
Oncology, pag. 23-37.
195. Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D'Armiento M, De Placido S. (2009).
Neoadjuvant treatment with capecitabine and oxaliplatin in combination with radiotherapy for rectal cancer patients: a phase II study.
Annals of Oncology, vol. 20, pag. 906-912.
196. Di Lorenzo G, Montesarchio V, Autorino R, Bellelli T, Longo N, Imbimbo C, Morelli E, Giannarini G, Mirone V, De Placido S (2009).
Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.
Cancer, pag. 517-523.

2008

197. Di Lorenzo G, Kreuter A, Di Trollo R, Guarini A, Romano C, Montesarchio V, Brockmeyer N, De Placido S, Bower M, Dezube Br.

Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. *Journal of Investigative Dermatology*, vol. 128, pag.1578-1580.

198. Perdonà S, Autorino R, Damiano R, De Sio M, Morrica B, Gallo L, Silvestro G, Farella A, De Placido S, Di Lorenzo G.
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
Cancer, vol. 112, pag. 75-83.

199. Di Lorenzo G, Figg W, Fossa S, Mirone V, Autorino R, Longo N, Imbimbo C, Perdonà S, Giordano A, Giuliano M, Labianca R, De Placido S.
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
European Urology, vol. 54, pag. 1089-1094.

200. Canello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G, Plaitano M, De Placido S, De Laurentiis M.
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.
Breast Cancer Research, vol. 10, pag. 1-8.

201. Di Lorenzo G, Di Trollo R, Montesarchio V, Palmieri G, Nappa P, Delfino M, De Placido S, Dezube BJ.
Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
Cancer, vol. 112, pag. 1147-1152.

202. De Laurentiis M, Canello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S.
Taxane- Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials.
Journal of Clinical Oncology, vol. 26, pag. 44-53 I.F 24.008.

203. Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, De Matteis A.
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Critical Reviews in Oncology, vol. 66, pag. 171-180.2007.

2007

204. Di Lorenzo G, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, De Stefano A, Esposito V, De Placido S, Montesarchio V. (2007).

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.

World Journal of Gastroenterology, vol. 13, pag. 6553-6557.

205. Di Lorenzo G, Autorino R, Perdona S, De Laurentiis M, D'armiento M, Cancellato G, Mirone V, Imbimbo C, Longo N, Altieri V, G. Tortora, Figg Wd, De Placido S (2007).

Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.

European Urology, vol. 52, pag. 1020-1027.

206. Di Lorenzo G, Autorino R, Figg W, De Placido S

Hormone-refractory prostate cancer: where are we going?

Drugs, vol. 67, pag. 1109-1124.

207. Veneziani BM, Criniti V, Cavaliere C, Corvigno S, Nardone A, Picarelli S, Tortora G, Ciardiello F, Limite G, De Placido S.

In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches.

Molecular Cancer Therapeutics, vol. 6, pag. 3091-3100.

208. Di Lorenzo G, Konstantinopoulos P, Pantanowitz L, Di Trollo R, De Placido S, Dezube B. Management of AIDS- related Kaposi's sarcoma.

Lancet Oncology, vol. 8, pag. 167-176.

209. Autorino R, Lamendola MG, De Luca G, De Sio M, Giuliano F, D' Armiento M, De Placido S, Conti P, Di Lorenzo G.

Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer. International Journal of Immunopathology and Pharmacology, vol. 20, pag. 765-770.

210. Di Lorenzo G, Autorino R, Giuliano M, Morelli E, Giordano A, Napodano G, Russo A, Benincasa G, D'armiento M, Altieri V, De Placido S.

Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.

Urology, vol. 69, pag. 347-351.

211. Di Lorenzo G, De Placido S. Re: Perabo FGE and Muller SC. New agents for treatment of advanced transitional cell carcinoma. Ann Oncol 2007; 18: 835-84

Annals of Oncology, vol. 18, pag. 1118-1127.

212. Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla Er, Agrawal S, Ciardiello F, G. Tortora.

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pag. 12468-12473.

213. Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, Giugliano F, Imbimbo C, Mirone V, De Placido S. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer. A phase I clinical trial.
Cancer Biology & Therapy, vol. 6, pag. 313-317.
214. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne K, Schiff R.
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER- targeted therapy.
Journal of the National Cancer Institute, vol. 99, pag. 694-705.

2006

215. Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani Bm, Fontanini G, Eckhardt SG, De Placido S, Tortora G, Ciardiello F.
Antitumor activity of the combination of cetuximab, an anti-egfr blocking monoclonal antibody and zd6474, an inhibitor of vegfr and egfr tyrosine kinases.
Journal of Cellular Physiology, vol. 208, pag. 344-353.
216. Carlomagno C, Orditura M, Pepe S, De Vita F, Romano C, Ciardiello F, Ferrara C, Martinelli E, Bianco R, Aurilio G, D'Agostino D, Tortora G, Catalano G, De Placido S.
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
American Journal of Clinical Oncology: CANCER CLINICAL TRIALS, vol. 29, p. 85-89.
217. Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
International Journal of Immunopathology and Pharmacology, vol. 19, pag. 11-34.
218. Damiano V, Caputo R, Bianco R, Darmiento F, Leonardi A, De Placido S, Bianco Ar, Agrawal S, Ciardiello F, G. Tortora.
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors.
Cancer Research, vol. 12, pag. 577-583.
219. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, G. Tortora, Palmieri G, De Vita F, Diadema Mr, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR.
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
British Journal of Cancer, vol. 94, pag.1604-1609.

220. Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Vernaglia Lombardi A, Manzione L, Cartenì G, Nardi M, Danese S, Valerio MR, De Matteis A, Massidda B, Gasparini G, Di Maio M, Pisano C, Perrone F.
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
BMC Cancer, vol. 6, pag. 5.
221. Di Trollo R, Di Lorenzo G, Delfino M, De Placido S.
Role of pegylated liposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.
International Journal of Immunopathology and Pharmacology, vol. 19, pag. 253-263.
222. Orditura M, Martinelli E, Galizia G, Carlomagno C, Aurilio G, Vecchione L, Lieto E, De Placido S, Catalano G, Ciardiello F, De Vita F (2006).
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Annals of Oncology, vol. 17, pag. 1529-1532.

2005

223. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'agostino D, Caputo F, Cancellò G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
Clinical Cancer Research, vol. 11, pag. 4741-4748.
224. De Vita F, Orditura M, Matano E, Bianco R., Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR. (2005).
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
British Journal of Cancer, vol. 92, pag. 1644-1649.
225. De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D'aprile M, Pistillucci G, Farris A, Sarobba Mg, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferrau F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco Ar, GOCSI COOPERATIVE GROUP.
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. British Journal of Cancer, vol. 92, pag. 467-474.

226. Massarelli E, Liu D, Lee J, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA (2005). Akt activation correlates with adverse outcome in tongue cancer. *Cancer*, vol. 104, pag. 2430-2436.
227. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco Ar, S. De Placido, Ciardiello F, Tortora G. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma *Clinical Cancer Research*, vol. 11, pag. 5639-5644.
228. Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repettos L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo. Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. *Tumori*, vol. 91, pag. 373-379.
229. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), De Laurentiis M, De Placido S. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*, vol. 365, pag. 1687-1717.
230. Perdonà S, Autorino R, De Placido S, D'armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco Ar, Di Lorenzo G. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. *Lancet Oncology*, vol. 6, pag. 295-300.
231. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. *Journal of the National Cancer Institute*, vol. 97, pag. 1254-1261.
232. Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'armiento M, Tortora G, De Rosa G, D'armiento M, De Sio M, Bianco Ar, F. D'armiento. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. *Prostate Cancer and Prostatic Diseases*, vol. 8, pag. 54-59.
233. Di Lorenzo G, Perdonà S, De Placido S, D'armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. *Journal of Urology*, vol. 174, pag. 2197-2203.

234. Di Lorenzo G, Autorino R, Perdona S, De Placido S. Management of gynaecomastia in patients with prostate cancer: a systematic review. *Lancet Oncology*, vol. 6, pag. 972-979.
235. De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello Gp, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini, M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco A.
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
British Journal of Cancer, vol. 93, pag. 896-904.
236. Autorino R, Di Lorenzo G, D'Armiento FP, Mignogna C, Cindolo L, De Sio M, Perdona S, De Fortuna E, Salzano L, De Placido S, D'Armiento M. Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer.
Minerva Urologica e Nefrologica, vol. 57, pag. 319-324.
237. Di Lorenzo G, Di Trollo R, Delfino M, De Placido S.
Pegylated liposomal doxorubicin in stage IVB mycosis fungoides.
British Journal of Dermatology, vol. 153, pag. 183-185.
238. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hocht-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group, De Laurentiis M, De Placido S, Carlomagno C.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Lancet, vol. 365, pag. 60-62.
239. De Laurentiis M, Cancellio G, Zinno L, Montagna E, Malorni L, Esposito A, Pennacchio R, Silvestro L, Giuliano M, Giordano A, Caputo F, Accurso A, De Placido S (2005).
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
Annals of Oncology, vol. 16, pag. iv7-iv13.
240. De Sio M, D'Armiento M, Di Lorenzo G, Damiano R, Perdona S., De Placido S, Autorino R.
The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know?
BJU International, vol. 96, pag. 977-983.
241. Danova M, Rosti G, De Placido S, Bencardino K, Venturini M. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists
Oncology Reports, vol. 14, pag. 1405-1412.
242. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani Bm, Bianco Ar, De Placido S, Ciardiello F, G. Tortora (2005).
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

2004

243. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, S. De Placido, Bianco Ar, Tortora G (2004).
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Clinical Cancer Research, vol. 10, pag. 784-793.
244. Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco Ar, Ciardiello F, Tortora G.
Combined targeting of egfr and mdm2 by gefitinib and antisense mdm2 cooperatively inhibit hormone- independent prostate cancer. Clinical Cancer Research, vol. 10, pag. 4858-4864
245. Di Lorenzo G, Autorino R, D'Armiento FP, Mignogna C, De Laurentiis M, De Sio M, D'Armiento M, Damiano R, Vecchio G, De Placido S.
Expression of proto-oncogene c-kit in high risk prostate cancer.
European Journal of Surgical Oncology, vol. 30, pag. 987-992.
246. Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'armiento M, Bianco AR, De Placido S.
FOLFOX-4 in pre- treated patients with advanced transitional cell carcinoma of the bladder.
Japanese Journal of Clinical Oncology, vol. 34, pag. 747-750.
247. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'armiento M, Bianco AR, De Placido S.
HER-2/neu receptor in prostate cancer development and progression to androgen independence.
Tumori, vol. 90, pag. 163-170 I.F.
248. Perrone F, Marangolo M, Di Costanzo F, Colucci G, Repetto L, Merlano M, De Placido S, Torri V, Comella G, Labianca R, Parisi V, Gallo C.
Insurance for independent cancer trials.
Annals of Oncology, vol. 15, pag. 1722-1723.
249. Barba M, Mccann S, Schünemann H, Stranges S, Fuhrman B, De Placido S, Carruba G, Freudenheim L, Trevisan M, Russell M, Nochajski T, Muti P.
Lifetime total and beverage specific--alcohol intake and prostate cancer risk: a case-control study.
Nutrition Journal, vol. 3, pag. 23.
250. Ippolito AM, De Laurentiis M, L La G, Eleuteri A, Tagliaferri R, De Placido S, Vigneri R, Belfiore A.
Neural network analysis for evaluating cancer risk in thyroid nodules with an indeterminate diagnosis at aspiration cytology: identification of a low-risk subgroup.

Thyroid, vol. 14, pag. 1065-1071.

251. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A, De Placido S.
Quality of Life of Postmenopausal the Women in the Arimidex, Tamoxifen, alone or in combination (ATAC) Adjuvant breast Cancer Trial.
Journal of Clinical Oncology, vol. 22, pag. 4261-4271.
252. De Placido S, Scambia SD, Di Vagno G, Naglieri G, Lombardi E, Biamonte R, Marinaccio M, Carteni G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio Mr, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. (2004).
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study
Journal of Clinical Oncology, vol. 22, pag. 2635-2642.
253. Di Lorenzo G, Pizza C, Autorino R, De Laurentiis M, Marano O, D'Alessio A, Cancelli G, Altieri V, Tortora G, Perdonà S, Bianco AR, De Placido S.
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. European Urology, vol. 46, pag. 712-716.

2003

254. Eleuteri A, Tagliaferri R, Milano L, S. De Placido, De Laurentiis M.
A Novel Neural Network-Based Survival Analysis Model. A novel neural network-based survival analysis model.
Neural Networks, vol. 16, pag. 855- 864.
255. De Sio M, Autorino R, Di Lorenzo G, Damiano R, Cosentino L, De Placido S, D'Armiento M.
Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma.
Urologia Internationalis, vol. 71, pag. 361- 367.
256. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group, De Laurentiis m, De Placido S, Carlomagno C (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Cancer, vol. 98, pag. 1802-1810.
257. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco AR.
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.

Clin Cancer Res. 2003 Mar; 9(3):1039-46.

258. Tortora G, Caputo R, Damiano V, Caputo R, Melisi D, Bianco R, Fontanini G, Veneziani Bm, De Placido S, Bianco Ar, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 ('Iressa') and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect. *Clinical Cancer Research*, pag. 1231-1232.
259. Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister- Wittke U, Ciardiello F. Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity. *Clinical Cancer Research*, pag. 866-871.
260. Ciardiello F, De Vita F, Orditura M, De Placido S, Tortora G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. *Expert Opinion on Emerging Drugs*, vol. 8, pag. 501-514.
261. Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T, Pizza C, De Laurentiis M, Pensabene M, D'Armiento M, Bianco AR, De Placido S. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. *Oncology Reports*, vol. 10, pag. 399-404.
262. Minenkova O, Pucci A, Pavoni E, De Tomassi A, Fortugno P, Gargano N, Cianfriglia M, Barca S, De Placido S, Martignetti A, Felici F, Cortese R, Monaci P. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. *International Journal of Cancer*, vol. 106, pag. 534-544.
263. Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S. (2003). Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. *Tumori*, vol. 89, pag. 349-360.

2002

264. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group, De Laurentiis M, De Placido S, Carlomagno C. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet*, vol. 359, pag. 2131-2139.

265. Di Lorenzo G, Tortora G, D'Armineto FP, De Rosa G, Staibano S, Autorino R, Darmiento M, De Laurentiis M, S. De Placido, Catalano G, Bianco AR, Ciardiello F.
Expression of Epidermal Growth Factor Receptor (EGFR) Correlates with disease relapse and progression to androgen—independence in human prostate cancer.
Clinical Cancer Research, vol. 8, pag. 3438-3444.
266. Tortora G, Ciardiello F, Damiano V, De Laurentiis M, Matano E, Pepe S, De Placido S, Catalano G, Bianco AR.
Preclinical and phase I study of Oxaliplatin and Topotecan in combination in human cancer.
Annals of Oncology, vol. 13, pag. 392-398.
267. Mustacchi G, Ceccherini R, Pluchinotta A, De Matteis A, Maiorino L, Farris A, Scanni A, De Placido S.
Results of adjuvant treatment in breast cancer women aged more than 70: Italian cooperative group experience.
Tumori, vol. 88, pag. S83-S85.
268. Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, Bianco AR, De Placido S.
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Oncology, vol. 63, pag. 219-225.
269. Ciardiello F, Tortora G, De Placido S, Bianco AR.
ZD1839 (Iressa): preclinical studies and pharmacology.
Tumori, vol. 88, pag. S155-S157.

2001

270. Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco Ar, Ciardiello F.
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Clinical Cancer Research, vol. 7, pag. 2537-2544.
271. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco Ar, Tortora G.
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Clinical Cancer Research, vol. 7, pag. 74-75.
272. Mosconi P, Colozza M, De Laurentiis M, De Placido S, Maltoni M.
Survival, quality of life and breast cancer.

2000

273. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatigo G, De Placido S, Bianco AR, Mendelsohn J, G. Tortora.
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells.
Clinical Cancer Research, vol. 6, pag. 3739-3747.
274. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F.
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti- epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Clinical Cancer Research, vol. 6, pag. 4343.
275. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatigo G, De Placido S, Bianco AR, Tortora G.
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor.
Clinical Cancer Research, vol. 6, pag. 2053-2063.
276. De Placido S, Tramontana S, Ferrari E, De Matteis A, Lauria R, Perrone F, Bianco AR, Gallo C, Ricchi P, De Placido G, S Pignata, G. C. T.
Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
Anticancer Research, vol. 20, pag. 4023-4029.
277. Pepe S, Ruggiero A, D'acquisto M, De Laurentiis M, De Placido S, Sandomenico C, Staibano S, De Rosa G, Lucariello A, D'armiento M, Bianco AR.
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas.
Cancer, vol. 89, pag. 1065-1075.
278. Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F.
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production.
Clinical Cancer Research, vol. 6, pag. 2506-2512.
279. Ciardiello F, Caputo R, Pomatigo G, De Laurentiis M, De Placido S, Bianco AR, Tortora G.
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined

treatment with an antisense oligonucleotide targeting protein kinase A.

Internarional Journal of Cancer, vol. 85, pag. 710-715.

280. De Placido S, Lauria R, Perrone F, Vernaglia Lombardi A, Carlomagno C, Varriale E, Costanzo R, Leo L, De Laurentiis M, Bianco AR. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. Oncology, vol. 58, pag. 8-14.

1999

281. De Laurentiis M, De Placido S, Bianco AR, Clark GM, Ravdin PM. A Prognostic Model that makes Quantitative Estimates of Probability of Relapse for Breast Cancer Patients. Clinical Cancer Research, vol. 5, pag. 4133- 4139.
282. Lauria R, Ferrari E, Tramontana S, Morabito A, Perrone F, Maffeo A, Fiorentino R, Casella G, Iodice F, Ricchi P, Carlomagno C, Varriale E, De Placido G, De Placido S, Bianco AR, Pignata S. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. Oncology, vol. 56, pag. 267-273.
283. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clinical Cancer Research, vol. 5, pag. 909-916.
284. De Placido S, Carlomagno C, Ciardiello F, De Laurentiis M, Pepe S, Ruggiero A, G. Tortora, Panico L, D' Antonio A, Pettinato G, Petrella G, Bianco AR. Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. Cancer Research, vol. 5, pag. 2854-2859.
285. De Placido S, Lauria R, Carlomagno C, Perrone F, De Laurentiis M, Gallo C, Martignetti A, Bellelli T, Limite G, Petrella G, Bianco AR. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. International Journal of Oncology, vol. 15, pag. 339-346.1998.

1998

286. No authors listed [CLIP Investigators]. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology, vol. 28, pag. 751-755.

287. Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De Placido S, Gallo C, Monfardini S, Bianco AR.
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study.
Gruppo Oncologico Centro-Sud-Isole
Journal of Clinical Oncology, vol. 16, pag. 1414-16.
288. Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F.
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.
Clinical Cancer Research, vol. 4, pag. 241-249.
289. No authors listed [CLIP Investigators].
Tamoxifen in the treatment of hepatocellular carcinoma: a multicenter randomized controlled trial.
Lancet, vol. 352, pag. 17-20.
290. De Placido S, Carlomagno C, De Laurentiis M, Bianco AR.
C-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.
Breast Cancer Research and Treatment, vol. 52, pag. 55-64.

1997

291. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study.
Journal of the National Cancer Institute, vol. 89, pag. 881-886.
292. Pignata S, Lauria R, Perrone F, Ferrari E, Biondi E, Maffeo A, Morabito A, Graziano R, Carlomagno C, De Placido G, Gallo C, Bianco AR, Pergola M, De Placido S.
Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer.
International Journal of Oncology, vol. 11, pag. 175-180.
293. Bianco AR, Carlomagno C, De Laurentiis M, De Placido S, Tortora G, Ciardiello F.
Prognostic factors in human colorectal cancer.
Tumori, vol. 83, pag. S15-S18.
294. Costantini M, Mencaglia E, Di Giulio P, Cortesi E, Roila F, Ballatori E, Tamburini M, Casali P, Licitra L, Massidda B, Luzzani M, Campora E, De

Placido S, Palmeri S, Palladino MA, Baracco G, Gareri R, Martignetti A, Ragosa S, Zoda L, Ionta MT, Bulletti S, Pastore L.
Evaluation of quality of life in oncology. Rationale and objectives of the first phase of the Quality of Life in Oncology project.
Tumori, vol. 83, pag. S25-S27.

295. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
J Clin Oncol. 1996 Oct; 14(10):2702-8. PMID: 8874330.

1996

296. De Laurentiis M, Gallo C, De Placido S, Perrone F, Pettinato G, Petrella G, Carlomagno C, Panico L, Delrio P, Bianco AR.
A predictive index of axillary nodal involvement in operable breast cancer.
British Journal of Cancer, vol. 73, pag. 1241-1247.
297. Caraglia M, Leardi A, Ricciardi B, De Laurentiis M, Lentini ML, Graziano, Matano E, De Placido S, Bianco AR, Tagliaferri P. A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.
Internarional Journal of Oncology, vol. 8, pag. 847-850.
298. De Michele G, Perrone F, Filla A, Mirante E, Giordano M, De Placido S, Campanella G.
Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients.
Neurology, vol. 47, pag. 1260-1264.
299. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Journal of the National Cancer Institute, vol. 88, pag. 1770-1776.
300. Giordano L, Giorgi D, Fasolo G, Segnan N, Rosselli Del Turco M, Bianco AR, De Placido S, Sodano A, Pini MT, Nuzzo F, Perrone F.
Breast cancer screening: characteristics and results of the Italian programmes in the Italian group for planning and evaluating breast cancer screening programmes (GISMa).
Tumori, vol. 82, pag. 31-37.
301. Panico L, D'Antonio A, Salvatore G, Mazza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, Gullick WJ, Pettinato G, BiancoAR, Ciardiello F.
Differential immunohistochemical detection of transforming growth factor α , amphiregulin and CRIPTO in human normal and malignant breast tissues.

International Journal of Cancer, vol. 65, pag. 51-56.

302. Gridelli C, Perrone F, Palmeri S, D'aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole" (G.O.C.S.I.). Annals of Oncology, vol. 7, pag. 821-826.

303. Catalano L, Improta S, De Laurentiis M, Molica S, Majolino I, Musto P, Fragasso A, De Placido S, Rotoli B. Prognosis of chronic myelomonocytic leukemia. Haematologica, vol. 81, pag. 324-329.

304. Perrone F, Carlomagno C, Lauria R, De Laurentiis M, Morabito A, Panico L, Pettinato G, G Petrella, Gallo C, Bianco AR, De Placido S. Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes?. European Journal of Cancer, vol. 32A, pag. 41-46.

305. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco A R, De Placido S. C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology, vol. 14, pag. 2702-2708.

1995

306. Perrone F, De Placido S, Gallo C, Carlomagno C, Lauria R, Bianco AR. Adjuvant chemoendocrine therapy for early breast cancer: is it worth while? International Journal of Oncology, vol. 7, pag. 1129-1137.

307. De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, Marinelli A, De Laurentiis M, Varriale E, Petrella G. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). British Journal of Cancer, vol. 71, pag. 1283-1287.

308. Pepe S, Ruggiero A, De Laurentiis M, Normanno N, Fiorentino B, Perrone F, Carlomagno C, De Placido S, Panico L, Pettinato G, Borriello G, Bianco AR. DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospective series of 515 primary breast cancer. Oncology Reports, vol. 2, pag. 345-359, ISSN: 1021-3355.

309. Perrone F, Carlomagno C, De Placido S, Lauria R, Morabito A, Bianco AR.
First-line systemic therapy for metastatic breast cancer and management of pleural effusion.
Annals of Oncology, vol. 6, pag. 1033-1043.
310. Gallo C, Perrone F, De Placido S, Gusti C.
Informed versus randomised consent to clinical trial.
The Lancet. 1995 Oct 21;346(8982):1060-4. PMID:7564786.
311. Tagliaferri P, Matano E, Rea A, Famiani M, Ciardiello F, Tortora G, Montesarchio V, Morabito A, Caraglia M, De Laurentiis M, De Placido S, Palmieri G, Bianco AR.
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
Oncology Reports, vol. 2, pag. 365-368.
312. Carlomagno C, Perrone F, Lauria R, De Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A, Putrella G, Bianco AR, De Placido S.
Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer.
Oncology, vol. 52, pag. 272-277.
313. De Placido S, Nuzzo F, Perrone F, Carlomagno C, Noviello A, Delrio P, Di Palma E, Pini MT, Cerato PL, Bianco C.
The first breast cancer screening program in southern Italy: preliminary results from three municipalities of the Naples Province. Tumori, vol. 81, pag. 7-12.
314. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, De Placido S.
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.
Cancer, vol. 76, pag. 1772-1778.
315. Perrone F, De Placido S, Giusti C, Gallo C
[The request for consent in clinical research: a randomized study in healthy subjects].
Epidemiologia e Prevenzione, vol. 19, pag. 282- 290.
316. Gridelli C, Perrone F, D'Aprile M, Palmeri S, Lo Russo V, Palmieri G, De Placido S, Gallo C, Bianco AR.
Phase II study of intensive CEV (carboplatino, epirubicina, and VP-16) plus G-CSF (Granulocyte-colony cell stimulatig factor) in extensive small cell lug cancer.
European Journal of Cancer, vol. 31a, pag. 2424-2426.

1994

317. Gridelli C, Ianniello GP, Maiorino A, Curcio C, D'Aprile M, Brancaccio L, Palmeri S, Gentile M, Comella G, Pedicini T, Airoma G, Veltri E, Gebbia V, Russo A, Casaretti R, Giampaglia F, Ferrante G, Rausa L, Iacobelli S, Arcangeli G, De Placido S, Bianco AR.
Carboplatin, epirubicin and VP-16 chemotherapy in the treatment of small cell lung cancer.
American Journal of Clinical Oncology: CANCER CLINICAL TRIALS, vol. 17, pag. 160-162 .
318. Perrone F, S De Placido, Carlomagno C, Gravina A, De Laurentiis M, Del Mastro L, Gridelli C, Pagliarulo C, Bianco AR. Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
American Journal of Clinical Oncology: CANCER CLINICAL TRIALS, vol. 17, pag. 218-222.
319. Morabito A, Perrone F, Lauria R, Carlomagno C, Marinelli A, De Laurentiis M, Martignetti A, Pettinato G., Panico L, Petrella G, Gallo C, Bianco AR, De Placido S.
Prognostic significance of multifocality in primary breast cancer.
Oncology Reports, pag. 1045-1048.

1993

320. Perrone F, De Placido S, Carlomagno C, Nuzzo F, Ruggiero A, De Laurentiis M, Gridelli C, Pagliarulo C, Bianco AR.
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.
Tumori, vol. 79, pag. 254-257.
321. Lorusso V, De Lena M, Lopez M, De Placido S, Vici P, Piano A, Palomba G, Carlomagno C, D'Aprile M, Fosser V, Brandi M, Bianco AR.
Combination chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5-Fluorouracil versus CNF (Mitoxantrone, Fluorouracil, Cyclophosphamide) in advanced breast cancer. A multicenter randomized study.
International Journal of Oncology, pag. 531-535.

1991

322. Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, Del Mastro L, Lauria R, Marinelli A, Gallo C.
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Annals of the New York Academy of Sciences, vol. 698, pag. 330-338.

323. Gridelli C, De Placido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G, Bianco AR.
Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.
European Journal of Cancer, vol. 29A, pag. 1729-1731.
324. Bianco AR, Rosso, Calabresi F, Fiorentino M, Lopez M, Sismondi PG, Lenti R, V Fossier, De Placido S, Perrone F.
LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). European Journal of Gynaecological Oncology, vol. 12, pag. 429-437.
325. Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G, Palmieri G, Russo A, Incoronato P, De Placido S, Perrone F, Basilico L, Rausa L, Ferrante G, Bianco AR.
Phase II study of mitomycin C, etoposide and vindesine (MEV) in metastatic, stage IV, non small cell lung cancer.
Cancer Chemotherapy and Pharmacology, vol. 28, pag. 405-407, ISSN: 0344-5704.
326. Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S.
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
European Journal of Gynaecological Oncology, vol. 63, pag. 799-803.
327. Gridelli C, Contegiacomo A, Lauria R, Gentile M, Airoma G, De Placido S, Perrone F, Ferrante G Bianco AR.
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
Tumori, vol. 77, pag. 506-510.

1990

328. Caponigro F, Iaffaioli V, Pagliarulo C, De Placido S, Frasci G, Ungaro B, Matano E, Bianco AR.
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
International Journal of Biological Markers, vol. 5, pag. 73-76.
329. De Placido S, Gallo C, Perrone F, Marinelli A, Pagliarulo C, Carlomagno C, Petrella G, D'Istria M, Delrio G, Bianco AR.
Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.
British Journal of Cancer, vol. 62, pag. 643-646.
330. S De Placido, Gallo C, Marinelli A, Perrone F, Pagliarulo C, Petrella G, Delrio G, D'Istria M, Del Mastro L, Bianco AR.

Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study.
Breast Cancer Research and Treatment, vol. 16, pag. 111-117.

1989

331. Lopez M, Contegiacomo A, Vici P, C Dello Iorio, Di Lauro L, Pagliarulo C, Carpano S, Giannarelli D, De Placido S, Fazio S.A Prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer.
Cancer, vol. 64, pag. 2431-2436.
332. Iaffaioli RV, Frasci G, Palmieri G, De Placido S, Mastrantonio P, Lombardi D, De Placido G, Montemagno U, Bianco AR.
The adjuvant treatment of ovarian cancer: result of the pilot study of a new combination chemotherapeutic regimen (DAC).
European Journal of Gynaecological Oncology, vol. 10, pag. 349-352.

1988

333. Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G.
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Lancet, vol. 2, pag.1095-1099.
334. Iaffaioli R V, Bianchin A, Ruggiero G, Pirozzi G, Ungaro A, Totaro G, Gallo C, De Placido S, Pagliarulo C, Bianco AR. Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients.
Oncology, vol. 45, pag. 337-343.

1987

335. Contegiacomo A, Fiorillo L, De Placido S, Pagliarulo C, Iaffaioli RV, Genua G, Giampaglia F, Palmieri G, Bianco AR.
The treatment of metastatic pleural effusion in breast cancer: report of 25 cases.
Tumori, vol. 73, pag. 611-617.

1986

336. Delrio G, De Placido S, Pagliarulo C, D'Istria M, Fasano S, Marinelli A, Citarella F, De Sio L, Contegiacomo A, Iaffaioli RV.
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.

Tumori, vol. 72, pag. 53-61.

1985

337. Bianco AR, S De Placido, Pagliarulo C, Fasano S, D'Istria M, De Sio L, Ricciardi I, Delrio G.
Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
Chemioterapia, vol. 4, pag. 252-255.

1978

338. Contieri E, Iodice R, Piscitelli L, Izzo R, De Placido S. [Association of gastric cancer and hepatitis. A theory to be verified].
Minerva Chirurgica, vol. 33, pag. 1077-1080.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03 e dall'art. 13 del GDPR (Regolamento UE 2016/679).

Napoli, 24/02/2021

FIRMA:

A handwritten signature in black ink, appearing to read 'Bellacò'.